A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients — Stella

Recruiting

Back to Glioblastoma (GBM) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Mayo Clinic Hospital, Phoenix, Arizona

Mayo Clinic Hospital, Jacksonville, Florida

Mayo Clinic Hospital, Rochester, Minnesota

Key details

Phase

Early testing / Safety & dosing

Sponsor

Myosin Therapeutics Inc.

Collaborators

Mayo Clinic, National Cancer Institute (NCI)

Enrollment target

~36 participants

Started

April 2026

Primary completion

October 2026

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov